11/12
09:07 am
espr
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/12
08:06 am
espr
Esperion Therapeutics (NASDAQ:ESPR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Esperion Therapeutics (NASDAQ:ESPR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
9/19
09:29 am
espr
Esperion Therapeutics (NASDAQ:ESPR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Esperion Therapeutics (NASDAQ:ESPR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.